Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation
  • Ask Questions

Author: CycloLab Ltd.

February 4, 2021 CD as API / Drug delivery / Events

Press Release – Development of Autophagy Inducing Cyclodextrin Derivatives for Aging-associated Diseases

CycloLab Cyclodextrin R&D Ltd. proudly announces winning of a national grant about the development of cyclodextrin-dervatives for autophagy-associated neurodegenerative diseases.

Continue reading

July 25, 2018 CD derivatives

Cyclodextrin Phosphates

In order to develop cyclodextrin derivatives having improved aqueous solubility, high solubilizing power, and low accumulation upon longer administration charged

Continue reading

July 25, 2018 Pharma applications / Supramolecular systems

Nanoaggregation on command

ScienceDaily reported on the effect of cyclodextrins as parts of synthetic receptors on the aggregation of proteins, recently published by

Continue reading

July 25, 2018 CD as API / Events / Pharma applications

Annual National Niemann Pick Disease Foundation Conference

Among several lectures useful for the families with member(s) suffering in rare diseases the ongoing clinical trials for NPC patients

Continue reading

Recent Posts

  • Registration opened for virtual abridged meeting prior to International Cyclodextrin Symposium
  • Visible Light-Activatable Cyclodextrin-Conjugates for the Efficient Delivery of Nitric Oxide with Fluorescent Reporter and their Inclusion Complexes with Betaxolol
  • Evading Thermodynamic Constraints of Cyclodextrin-Drug Formulations
  • Cyclodextrins in Antiviral Therapeutics and Vaccines
  • FDA granted accelerated approval to umbralisib / HPBCD tablet

Tags

antiviral Biotechnology Cancer therapy Captisol Cholesterol Clinical trial conference coronavirus Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems Drugs FDA Food Gilead History HPBCD nanomedicine Nanoparticles nanotechnology Niemann Pick Disease Polymer remdesivir SBECD Special issue Synthesis Trappsol

Follow Us

  • LinkedIn
  • Twitter
  • Facebook

Categories

  • Agriculture (9)
  • Analysis (14)
  • CD as API (106)
  • CD derivatives (140)
  • Cosmetics and toilettry (10)
  • Drug delivery (210)
  • E-ducation (41)
  • Environmental (44)
  • Events (102)
  • Food (60)
  • Gene delivery (6)
  • In Hungarian (4)
  • Non-pharma applications (103)
  • Other industrial use (36)
  • Pharma applications (373)
  • Supramolecular systems (7)
  • Uncategorized (23)

Top Posts

  • Registration opened for virtual abridged meeting prior to International Cyclodextrin Symposium
  • Visible Light-Activatable Cyclodextrin-Conjugates for the Efficient Delivery of Nitric Oxide with Fluorescent Reporter and their Inclusion Complexes with Betaxolol
  • Cyclodextrins in Antiviral Therapeutics and Vaccines
  • Evading Thermodynamic Constraints of Cyclodextrin-Drug Formulations
  • FDA granted accelerated approval to umbralisib / HPBCD tablet
  • The monograph of SBECD is official in the European Pharmacopeia
  • Nasal delivery with beta-cyclodextrin is approved; a short story of Baqsimi
  • How air fresheners work?
  • Reviews on cyclodextrin-metal-organic frameworks (CD-MOFs) in food applications
  • Host-guest chemistry for the treatment of leishmania

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 295 other subscribers